Clinical Trial Detail

NCT ID NCT02648490
Title An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Henlix, Inc
Indications

carcinoma

Advanced Solid Tumor

Therapies

Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron

HLX07

Age Groups: adult

Additional content available in CKB BOOST